---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004224"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:29:04.140191+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alaunos doubles TCR library addressable market; cash runway into Q4 2023

## Summary
- Added two new TCRs to library, doubling addressable market; targets KRAS, TP53, EGFR hotspot mutations.
- Enrolling patients in TCR-T Phase 1/2; third patient dosed Dec 2022; interim data expected mid-2023.
- Manufacturing capacity doubled; moving to cryopreserved product reduces process time 13% (30 to 26 days).
- mbIL-15 program IND filing anticipated H2 2023.
- Cash $39.1M (unaudited) plus $13.9M restricted; runway into Q4 2023; operating cash flow $35-40M in 2023.

## SEC filing metadata
- accession: 0001193125-23-004224
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523004224/0001193125-23-004224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523004224/d410539d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004224
- JSON: https://secwatch.observer/filing/0001193125-23-004224.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.